메뉴 건너뛰기




Volumn 26, Issue 9, 2007, Pages 1195-1208

Clinical trial: Switch to combined mycophenolate mofetil and minimal dose calcineurin inhibitor in stable liver transplant patients - Assessment of renal and allograft function, cardiovascular risk factors and immune monitoring

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CREATININE; CYCLOSPORIN A; LIVER ENZYME; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

EID: 35448943140     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2007.03466.x     Document Type: Article
Times cited : (51)

References (66)
  • 1
    • 33846323973 scopus 로고    scopus 로고
    • Review article: Medical management of the liver transplant recipient - A primer for non-transplant doctors
    • Sethi A, Stravitz RT. Review article: medical management of the liver transplant recipient - a primer for non-transplant doctors. Aliment Pharmacol Ther 2007 25 : 229 45.
    • (2007) Aliment Pharmacol Ther , vol.25 , pp. 229-45
    • Sethi, A.1    Stravitz, R.T.2
  • 2
    • 33745818408 scopus 로고    scopus 로고
    • Primer: Histopathology of calcineurin-inhibitor toxicity in renal allografts
    • Liptak P, Ivanyi B. Primer: histopathology of calcineurin-inhibitor toxicity in renal allografts. Nat Clin Pract Nephrol 2006 2 : 398 404.
    • (2006) Nat Clin Pract Nephrol , vol.2 , pp. 398-404
    • Liptak, P.1    Ivanyi, B.2
  • 4
    • 16244365873 scopus 로고    scopus 로고
    • Immunosuppression in liver transplantation: Beyond calcineurin inhibitors
    • Fung J, Kelly D, Kadry Z, Patel-Tom K, Eghtesad B. Immunosuppression in liver transplantation: beyond calcineurin inhibitors. Liver Transpl 2005 11 : 267 80.
    • (2005) Liver Transpl , vol.11 , pp. 267-80
    • Fung, J.1    Kelly, D.2    Kadry, Z.3    Patel-Tom, K.4    Eghtesad, B.5
  • 6
    • 26644433876 scopus 로고    scopus 로고
    • Long-term outcome of adding mycophenolate mofetil to tacrolimus for nephrotoxicity following liver transplantation
    • Jain A, Vekatramanan R, Eghtesad B, et al. Long-term outcome of adding mycophenolate mofetil to tacrolimus for nephrotoxicity following liver transplantation. Transplantation 2005 80 : 859 64.
    • (2005) Transplantation , vol.80 , pp. 859-64
    • Jain, A.1    Vekatramanan, R.2    Eghtesad, B.3
  • 7
    • 10344250408 scopus 로고    scopus 로고
    • Introduction of MMF in conjunction with stepwise reduction of calcineurin inhibitor in stable liver transplant patients with renal dysfunction
    • Kornberg A, Kupper B, Hommann M, Scheele J. Introduction of MMF in conjunction with stepwise reduction of calcineurin inhibitor in stable liver transplant patients with renal dysfunction. Int Immunopharmacol 2005 5 : 141 6.
    • (2005) Int Immunopharmacol , vol.5 , pp. 141-6
    • Kornberg, A.1    Kupper, B.2    Hommann, M.3    Scheele, J.4
  • 8
    • 0037962306 scopus 로고    scopus 로고
    • Efficacy of mycophenolate mofetil combined with very low-dose cyclosporine microemulsion in long-term liver-transplant patients with renal dysfunction
    • Cantarovich M, Tzimas GN, Barkun J, Deschenes M, Alpert E, Tchervenkov J. Efficacy of mycophenolate mofetil combined with very low-dose cyclosporine microemulsion in long-term liver-transplant patients with renal dysfunction. Transplantation 2003 76 : 98 102.
    • (2003) Transplantation , vol.76 , pp. 98-102
    • Cantarovich, M.1    Tzimas, G.N.2    Barkun, J.3    Deschenes, M.4    Alpert, E.5    Tchervenkov, J.6
  • 9
    • 27644566143 scopus 로고    scopus 로고
    • Mechanisms of action of mycophenolate mofetil in preventing acute and chronic allograft rejection
    • Allison AC, Eugui EM. Mechanisms of action of mycophenolate mofetil in preventing acute and chronic allograft rejection. Transplantation 2005 80 : S181 90.
    • (2005) Transplantation , vol.80
    • Allison, A.C.1    Eugui, E.M.2
  • 11
    • 0034045586 scopus 로고    scopus 로고
    • Mycophenolate mofetil and its mechanisms of action
    • Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000 47 : 85 118.
    • (2000) Immunopharmacology , vol.47 , pp. 85-118
    • Allison, A.C.1    Eugui, E.M.2
  • 12
    • 34247264458 scopus 로고    scopus 로고
    • In vitro evidence for a direct anti-fibrotic role of the immunosupressive drug mycophenolate mofetil
    • Roos N, Poulalhon N, Farge D, Madelaine I, Mauviel A, Verrecchia F. In vitro evidence for a direct anti-fibrotic role of the immunosupressive drug mycophenolate mofetil. J Pharmacol Exp Ther 2007 321 : 583 9.
    • (2007) J Pharmacol Exp Ther , vol.321 , pp. 583-9
    • Roos, N.1    Poulalhon, N.2    Farge, D.3    Madelaine, I.4    Mauviel, A.5    Verrecchia, F.6
  • 14
    • 4644360418 scopus 로고    scopus 로고
    • Effect of immunosuppressive agents on long-term survival of renal transplant recipients: Focus on the cardiovascular risk
    • Boots JM, Christiaans MH, van Hooff JP. Effect of immunosuppressive agents on long-term survival of renal transplant recipients: focus on the cardiovascular risk. Drugs 2004 64 : 2047 73.
    • (2004) Drugs , vol.64 , pp. 2047-73
    • Boots, J.M.1    Christiaans, M.H.2    Van Hooff, J.P.3
  • 15
    • 0032744204 scopus 로고    scopus 로고
    • Fibrogenic effects of cyclosporin a on the tubulointerstitium: Role of cytokines and growth factors
    • Johnson DW, Saunders HJ, Johnson FJ, Huq SO, Field MJ, Pollock CA. Fibrogenic effects of cyclosporin A on the tubulointerstitium: role of cytokines and growth factors. Exp Nephrol 1999 7 : 470 8.
    • (1999) Exp Nephrol , vol.7 , pp. 470-8
    • Johnson, D.W.1    Saunders, H.J.2    Johnson, F.J.3    Huq, S.O.4    Field, M.J.5    Pollock, C.A.6
  • 16
    • 0032892816 scopus 로고    scopus 로고
    • Cyclosporin exerts a direct fibrogenic effect on human tubulointerstitial cells: Roles of insulin-like growth factor I, transforming growth factor beta1, and platelet-derived growth factor
    • Johnson DW, Saunders HJ, Johnson FJ, Huq SO, Field MJ, Pollock CA. Cyclosporin exerts a direct fibrogenic effect on human tubulointerstitial cells: roles of insulin-like growth factor I, transforming growth factor beta1, and platelet-derived growth factor. J Pharmacol Exp Ther 1999 289 : 535 42.
    • (1999) J Pharmacol Exp Ther , vol.289 , pp. 535-42
    • Johnson, D.W.1    Saunders, H.J.2    Johnson, F.J.3    Huq, S.O.4    Field, M.J.5    Pollock, C.A.6
  • 18
    • 11144249899 scopus 로고    scopus 로고
    • Impact of combined mycophenolate mofetil and low-dose calcineurin inhibitor therapy on renal function, cardiovascular risk factors, and graft function in liver transplant patients: Preliminary results of an open prospective study
    • Beckebaum S, Cicinnati VR, Klein CG, et al. Impact of combined mycophenolate mofetil and low-dose calcineurin inhibitor therapy on renal function, cardiovascular risk factors, and graft function in liver transplant patients: preliminary results of an open prospective study. Transplant Proc 2004 36 : 2671 4.
    • (2004) Transplant Proc , vol.36 , pp. 2671-4
    • Beckebaum, S.1    Cicinnati, V.R.2    Klein, C.G.3
  • 19
    • 0034657919 scopus 로고    scopus 로고
    • Improvement of acute and chronic renal dysfunction in liver transplant patients after substitution of calcineurin inhibitors by mycophenolate mofetil
    • Barkmann A, Nashan B, Schmidt HH, et al. Improvement of acute and chronic renal dysfunction in liver transplant patients after substitution of calcineurin inhibitors by mycophenolate mofetil. Transplantation 2000 69 : 1886 90.
    • (2000) Transplantation , vol.69 , pp. 1886-90
    • Barkmann, A.1    Nashan, B.2    Schmidt, H.H.3
  • 20
    • 0035941732 scopus 로고    scopus 로고
    • Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: A randomised controlled study
    • Schlitt HJ, Barkmann A, Boker KH, et al. Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: a randomised controlled study. Lancet 2001 357 : 587 91.
    • (2001) Lancet , vol.357 , pp. 587-91
    • Schlitt, H.J.1    Barkmann, A.2    Boker, K.H.3
  • 21
    • 0035941756 scopus 로고    scopus 로고
    • Mycophenolate mofetil monotherapy in liver transplantation
    • Stewart SF, Hudson M, Talbot D, Manas D, Day CP. Mycophenolate mofetil monotherapy in liver transplantation. Lancet 2001 357 : 609 10.
    • (2001) Lancet , vol.357 , pp. 609-10
    • Stewart, S.F.1    Hudson, M.2    Talbot, D.3    Manas, D.4    Day, C.P.5
  • 22
    • 0032867160 scopus 로고    scopus 로고
    • Conversion of liver transplant recipients on cyclosporine with renal impairment to mycophenolate mofetil
    • Herrero JI, Quiroga J, Sangro B, et al. Conversion of liver transplant recipients on cyclosporine with renal impairment to mycophenolate mofetil. Liver Transpl Surg 1999 5 : 414 20.
    • (1999) Liver Transpl Surg , vol.5 , pp. 414-20
    • Herrero, J.I.1    Quiroga, J.2    Sangro, B.3
  • 23
    • 4744355008 scopus 로고    scopus 로고
    • Mycophenolate mofetil can be used as monotherapy late after liver transplantation
    • Moreno Planas JM, Cuervas-Mons MV, Rubio GE, et al. Mycophenolate mofetil can be used as monotherapy late after liver transplantation. Am J Transplant 2004 4 : 1650 5.
    • (2004) Am J Transplant , vol.4 , pp. 1650-5
    • Moreno Planas, J.M.1    Cuervas-Mons, M.V.2    Rubio, G.E.3
  • 24
    • 0037467787 scopus 로고    scopus 로고
    • Long-term mycophenolate mofetil monotherapy in combination with calcineurin inhibitors for chronic renal dysfunction after liver transplantation
    • Raimondo ML, Dagher L, Papatheodoridis GV, et al. Long-term mycophenolate mofetil monotherapy in combination with calcineurin inhibitors for chronic renal dysfunction after liver transplantation. Transplantation 2003 75 : 186 90.
    • (2003) Transplantation , vol.75 , pp. 186-90
    • Raimondo, M.L.1    Dagher, L.2    Papatheodoridis, G.V.3
  • 25
    • 4544361829 scopus 로고    scopus 로고
    • Mycophenolate mofetil monotherapy in liver transplant recipients: A single center experience
    • Fairbanks KD, Thuluvath PJ. Mycophenolate mofetil monotherapy in liver transplant recipients: a single center experience. Liver Transpl 2004 10 : 1189 94.
    • (2004) Liver Transpl , vol.10 , pp. 1189-94
    • Fairbanks, K.D.1    Thuluvath, P.J.2
  • 27
    • 33845516689 scopus 로고    scopus 로고
    • Mycophenolate mofetil in combination with reduction of calcineurin inhibitors for chronic renal dysfunction after liver transplantation
    • Pageaux GP, Rostaing L, Calmus Y, et al. Mycophenolate mofetil in combination with reduction of calcineurin inhibitors for chronic renal dysfunction after liver transplantation. Liver Transpl 2006 12 : 1755 60.
    • (2006) Liver Transpl , vol.12 , pp. 1755-60
    • Pageaux, G.P.1    Rostaing, L.2    Calmus, Y.3
  • 28
    • 22144490224 scopus 로고    scopus 로고
    • Mycophenolate mofetil for renal dysfunction in liver transplant recipients on cyclosporine or tacrolimus: Randomized, prospective, multicenter pilot study results
    • Reich DJ, Clavien PA, Hodge EE. Mycophenolate mofetil for renal dysfunction in liver transplant recipients on cyclosporine or tacrolimus: randomized, prospective, multicenter pilot study results. Transplantation 2005 80 : 18 25.
    • (2005) Transplantation , vol.80 , pp. 18-25
    • Reich, D.J.1    Clavien, P.A.2    Hodge, E.E.3
  • 29
    • 0035881234 scopus 로고    scopus 로고
    • Regulatory T cells induced by 1 alpha,25-dihydroxyvitamin D3 and mycophenolate mofetil treatment mediate transplantation tolerance
    • Gregori S, Casorati M, Amuchastegui S, Smiroldo S, Davalli AM, Adorini L. Regulatory T cells induced by 1 alpha,25-dihydroxyvitamin D3 and mycophenolate mofetil treatment mediate transplantation tolerance. J Immunol 2001 167 : 1945 53.
    • (2001) J Immunol , vol.167 , pp. 1945-53
    • Gregori, S.1    Casorati, M.2    Amuchastegui, S.3    Smiroldo, S.4    Davalli, A.M.5    Adorini, L.6
  • 30
    • 0030052899 scopus 로고    scopus 로고
    • Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club
    • Arroyo V, Gines P, Gerbes AL, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology 1996 23 : 164 76.
    • (1996) Hepatology , vol.23 , pp. 164-76
    • Arroyo, V.1    Gines, P.2    Gerbes, A.L.3
  • 31
    • 34548120893 scopus 로고    scopus 로고
    • Diagnosis, prevention and treatment of the hepatorenal syndrome in cirrhosis. a consensus workshop of the international ascites club
    • in press.
    • Salerno F, Gerbes A, Gines P, Wong F, Arroyo V. Diagnosis, prevention and treatment of the hepatorenal syndrome in cirrhosis. A consensus workshop of the international ascites club. Gut 2007 in press.
    • (2007) Gut
    • Salerno, F.1    Gerbes, A.2    Gines, P.3    Wong, F.4    Arroyo, V.5
  • 32
    • 0033865136 scopus 로고    scopus 로고
    • The 1997 American Diabetes Association and 1999 World Health Organization criteria for hyperglycemia in the diagnosis and prediction of diabetes
    • Gabir MM, Hanson RL, Dabelea D, et al. The 1997 American Diabetes Association and 1999 World Health Organization criteria for hyperglycemia in the diagnosis and prediction of diabetes. Diabetes Care 2000 23 : 1108 12.
    • (2000) Diabetes Care , vol.23 , pp. 1108-12
    • Gabir, M.M.1    Hanson, R.L.2    Dabelea, D.3
  • 33
    • 0001106451 scopus 로고    scopus 로고
    • A simplified equation to predict glomerular filtration rate from serum creatinine
    • MDRD Study Group.
    • Levey AS, Greene T, Kusek JW, Beck GJ, MDRD Study Group. A simplified equation to predict glomerular filtration rate from serum creatinine. Am Soc Nephrol 2000 11 : A0828.
    • (2000) Am Soc Nephrol , vol.11
    • Levey, A.S.1    Greene, T.2    Kusek, J.W.3    Beck, G.J.4
  • 34
    • 34147205677 scopus 로고    scopus 로고
    • Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values
    • Levey AS, Coresh J, Greene T, et al. Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem 2007 53 : 766 72.
    • (2007) Clin Chem , vol.53 , pp. 766-72
    • Levey, A.S.1    Coresh, J.2    Greene, T.3
  • 35
    • 0036176161 scopus 로고    scopus 로고
    • K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification
    • National Kidney Foundation.
    • National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002 39 : S1 266.
    • (2002) Am J Kidney Dis , vol.39
  • 36
    • 13144252194 scopus 로고    scopus 로고
    • MMF and calcineurin taper in recurrent hepatitis C after liver transplantation: Impact on histological course
    • Bahra M, Neumann UI, Jacob D, et al. MMF and calcineurin taper in recurrent hepatitis C after liver transplantation: impact on histological course. Am J Transplant 2005 5 : 406 11.
    • (2005) Am J Transplant , vol.5 , pp. 406-11
    • Bahra, M.1    Neumann, U.I.2    Jacob, D.3
  • 37
    • 0038824912 scopus 로고    scopus 로고
    • Independent risk factors and natural history of renal dysfunction in liver transplant recipients
    • Pawarode A, Fine DM, Thuluvath PJ. Independent risk factors and natural history of renal dysfunction in liver transplant recipients. Liver Transpl 2003 9 : 741 7.
    • (2003) Liver Transpl , vol.9 , pp. 741-7
    • Pawarode, A.1    Fine, D.M.2    Thuluvath, P.J.3
  • 38
    • 33745091541 scopus 로고    scopus 로고
    • Renal function in renal or liver transplant recipients after conversion from a calcineurin inhibitor to sirolimus
    • Backman L, Reisaeter AV, Wramner L, Ericzon BG, Salmela K, Brattstrom C. Renal function in renal or liver transplant recipients after conversion from a calcineurin inhibitor to sirolimus. Clin Transplant 2006 20 : 336 9.
    • (2006) Clin Transplant , vol.20 , pp. 336-9
    • Backman, L.1    Reisaeter, A.V.2    Wramner, L.3    Ericzon, B.G.4    Salmela, K.5    Brattstrom, C.6
  • 39
    • 0038638388 scopus 로고    scopus 로고
    • Mycophenolatemofetil for immunosuppression after liver transplantation: A follow-up study of 191 patients
    • Pfitzmann R, Klupp J, Langrehr JM, et al. Mycophenolatemofetil for immunosuppression after liver transplantation: a follow-up study of 191 patients. Transplantation 2003 76 : 130 6.
    • (2003) Transplantation , vol.76 , pp. 130-6
    • Pfitzmann, R.1    Klupp, J.2    Langrehr, J.M.3
  • 41
    • 0036424451 scopus 로고    scopus 로고
    • Mycophenolic acid antagonizes the activation of cultured human mesangial cells
    • Dubus I, Vendrely B, Christophe I, et al. Mycophenolic acid antagonizes the activation of cultured human mesangial cells. Kidney Int 2002 62 : 857 67.
    • (2002) Kidney Int , vol.62 , pp. 857-67
    • Dubus, I.1    Vendrely, B.2    Christophe, I.3
  • 42
    • 0031759148 scopus 로고    scopus 로고
    • Mycophenolic acid: A new approach to the therapy of experimental mesangial proliferative glomerulonephritis
    • Ziswiler R, Steinmann-Niggli K, Kappeler A, Daniel C, Marti HP. Mycophenolic acid: a new approach to the therapy of experimental mesangial proliferative glomerulonephritis. J Am Soc Nephrol 1998 9 : 2055 66.
    • (1998) J Am Soc Nephrol , vol.9 , pp. 2055-66
    • Ziswiler, R.1    Steinmann-Niggli, K.2    Kappeler, A.3    Daniel, C.4    Marti, H.P.5
  • 43
    • 0031725135 scopus 로고    scopus 로고
    • Mycophenolate mofetil prevents the induction of active Heymann nephritis: Association with Th2 cytokine inhibition
    • Penny MJ, Boyd RA, Hall BM. Mycophenolate mofetil prevents the induction of active Heymann nephritis: association with Th2 cytokine inhibition. J Am Soc Nephrol 1998 9 : 2272 82.
    • (1998) J Am Soc Nephrol , vol.9 , pp. 2272-82
    • Penny, M.J.1    Boyd, R.A.2    Hall, B.M.3
  • 45
    • 0033920978 scopus 로고    scopus 로고
    • Mycophenolate mofetil reduces myofibroblast infiltration and collagen III deposition in rat remnant kidney
    • Badid C, Vincent M, McGregor B, et al. Mycophenolate mofetil reduces myofibroblast infiltration and collagen III deposition in rat remnant kidney. Kidney Int 2000 58 : 51 61.
    • (2000) Kidney Int , vol.58 , pp. 51-61
    • Badid, C.1    Vincent, M.2    McGregor, B.3
  • 46
    • 33846189299 scopus 로고    scopus 로고
    • Mycophenolate mofetil is associated with altered expression of chronic renal transplant histology
    • Nankivell BJ, Wavamunno MD, Borrows RJ, et al. Mycophenolate mofetil is associated with altered expression of chronic renal transplant histology. Am J Transplant 2007 7 : 366 76.
    • (2007) Am J Transplant , vol.7 , pp. 366-76
    • Nankivell, B.J.1    Wavamunno, M.D.2    Borrows, R.J.3
  • 47
    • 0034839076 scopus 로고    scopus 로고
    • Mycophenolate mofetil: Implications for the treatment of glomerular disease
    • Badid C, Desmouliere A, Laville M. Mycophenolate mofetil: implications for the treatment of glomerular disease. Nephrol Dial Transplant 2001 16 : 1752 6.
    • (2001) Nephrol Dial Transplant , vol.16 , pp. 1752-6
    • Badid, C.1    Desmouliere, A.2    Laville, M.3
  • 48
    • 0036186923 scopus 로고    scopus 로고
    • Mycophenolate mofetil treatment for primary glomerular diseases
    • Choi MJ, Eustace JA, Gimenez LF, et al. Mycophenolate mofetil treatment for primary glomerular diseases. Kidney Int 2002 61 : 1098 114.
    • (2002) Kidney Int , vol.61 , pp. 1098-114
    • Choi, M.J.1    Eustace, J.A.2    Gimenez, L.F.3
  • 49
    • 0036780469 scopus 로고    scopus 로고
    • Cyclosporin a toxicity of the renal allograft - A late complication and potentially reversible
    • Sommerer C, Hergesell O, Nahm AM, et al. Cyclosporin A toxicity of the renal allograft - a late complication and potentially reversible. Nephron 2002 92 : 339 45.
    • (2002) Nephron , vol.92 , pp. 339-45
    • Sommerer, C.1    Hergesell, O.2    Nahm, A.M.3
  • 50
    • 33846222371 scopus 로고    scopus 로고
    • Switch to 1.5 grams MMF monotherapy for CNI-related toxicity in liver transplantation is safe and improves renal function, dyslipidemia, and hypertension
    • Orlando G, Baiocchi L, Cardillo A, et al. Switch to 1.5 grams MMF monotherapy for CNI-related toxicity in liver transplantation is safe and improves renal function, dyslipidemia, and hypertension. Liver Transpl 2007 13 : 46 54.
    • (2007) Liver Transpl , vol.13 , pp. 46-54
    • Orlando, G.1    Baiocchi, L.2    Cardillo, A.3
  • 51
    • 0029609949 scopus 로고
    • Mycophenolate mofetil (MMF, RS-61443) inhibits inflammation and smooth muscle cell proliferation in rat aortic allografts
    • Raisanen-Sokolowski A, Vuoristo P, Myllarniemi M, Yilmaz S, Kallio E, Hayry P. Mycophenolate mofetil (MMF, RS-61443) inhibits inflammation and smooth muscle cell proliferation in rat aortic allografts. Transpl Immunol 1995 3 : 342 51.
    • (1995) Transpl Immunol , vol.3 , pp. 342-51
    • Raisanen-Sokolowski, A.1    Vuoristo, P.2    Myllarniemi, M.3    Yilmaz, S.4    Kallio, E.5    Hayry, P.6
  • 52
    • 0032987171 scopus 로고    scopus 로고
    • Mycophenolate mofetil impairs transendothelial migration of allogeneic CD4 and CD8 T-cells
    • Blaheta RA, Leckel K, Wittig B, et al. Mycophenolate mofetil impairs transendothelial migration of allogeneic CD4 and CD8 T-cells. Transplant Proc 1999 31 : 1250 2.
    • (1999) Transplant Proc , vol.31 , pp. 1250-2
    • Blaheta, R.A.1    Leckel, K.2    Wittig, B.3
  • 53
    • 33644616547 scopus 로고    scopus 로고
    • Sequential determination of pharmacokinetics and pharmacodynamics of mycophenolic acid in liver transplant patients treated with mycophenolate mofetil
    • Brunet M, Cirera I, Martorell J, et al. Sequential determination of pharmacokinetics and pharmacodynamics of mycophenolic acid in liver transplant patients treated with mycophenolate mofetil. Transplantation 2006 81 : 541 6.
    • (2006) Transplantation , vol.81 , pp. 541-6
    • Brunet, M.1    Cirera, I.2    Martorell, J.3
  • 54
    • 0141727464 scopus 로고    scopus 로고
    • Mycophenolate mofetil severely depresses antibody response to CMV infection in early posttransplant period
    • Zmonarski SC, Boratynska M, Madziarska K, et al. Mycophenolate mofetil severely depresses antibody response to CMV infection in early posttransplant period. Transplant Proc 2003 35 : 2205 6.
    • (2003) Transplant Proc , vol.35 , pp. 2205-6
    • Zmonarski, S.C.1    Boratynska, M.2    Madziarska, K.3
  • 55
    • 0242552696 scopus 로고    scopus 로고
    • Histologic features of mycophenolate mofetil-related colitis: A graft-versus-host disease-like pattern
    • Papadimitriou JC, Cangro CB, Lustberg A, et al. Histologic features of mycophenolate mofetil-related colitis: a graft-versus-host disease-like pattern. Int J Surg Pathol 2003 11 : 295 302.
    • (2003) Int J Surg Pathol , vol.11 , pp. 295-302
    • Papadimitriou, J.C.1    Cangro, C.B.2    Lustberg, A.3
  • 56
    • 0037624810 scopus 로고    scopus 로고
    • A possible mechanism of gastrointestinal toxicity posed by mycophenolic acid
    • Neerman MF, Boothe DM. A possible mechanism of gastrointestinal toxicity posed by mycophenolic acid. Pharmacol Res 2003 47 : 523 6.
    • (2003) Pharmacol Res , vol.47 , pp. 523-6
    • Neerman, M.F.1    Boothe, D.M.2
  • 57
    • 35448946447 scopus 로고    scopus 로고
    • Relationship between plasma concentrations of mycophenolic acid (MPA) and its acyl glucuronide (AcMPAG) and intestinal damage in wistar rats treated with mycophenolate mofetil (MMF)
    • Shipkova M, Voland A, Grone HJ, Armstrong VW, Oellerich M, Wieland E. Relationship between plasma concentrations of mycophenolic acid (MPA) and its acyl glucuronide (AcMPAG) and intestinal damage in wistar rats treated with mycophenolate mofetil (MMF). Ther Drug Monit 2002 25 : 537.
    • (2002) Ther Drug Monit , vol.25 , pp. 537
    • Shipkova, M.1    Voland, A.2    Grone, H.J.3    Armstrong, V.W.4    Oellerich, M.5    Wieland, E.6
  • 58
    • 0042235130 scopus 로고    scopus 로고
    • Anemia in children after transplantation: Etiology and the effect of immunosuppressive therapy on erythropoiesis
    • Al-Uzri A, Yorgin PD, Kling PJ. Anemia in children after transplantation: etiology and the effect of immunosuppressive therapy on erythropoiesis. Pediatr Transplant 2003 7 : 253 64.
    • (2003) Pediatr Transplant , vol.7 , pp. 253-64
    • Al-Uzri, A.1    Yorgin, P.D.2    Kling, P.J.3
  • 59
    • 0030294654 scopus 로고    scopus 로고
    • Cytotoxic gammadelta or alphabeta T cells with a natural killer cell marker, CD56, induced from human peripheral blood lymphocytes by a combination of IL-12 and IL-2
    • Satoh M, Seki S, Hashimoto W, et al. Cytotoxic gammadelta or alphabeta T cells with a natural killer cell marker, CD56, induced from human peripheral blood lymphocytes by a combination of IL-12 and IL-2. J Immunol 1996 157 : 3886 92.
    • (1996) J Immunol , vol.157 , pp. 3886-92
    • Satoh, M.1    Seki, S.2    Hashimoto, W.3
  • 60
    • 0034937493 scopus 로고    scopus 로고
    • Systematic characterization of human CD8+ T cells with natural killer cell markers in comparison with natural killer cells and normal CD8+ T cells
    • Ohkawa T, Seki S, Dobashi H, et al. Systematic characterization of human CD8+ T cells with natural killer cell markers in comparison with natural killer cells and normal CD8+ T cells. Immunology 2001 103 : 281 90.
    • (2001) Immunology , vol.103 , pp. 281-90
    • Ohkawa, T.1    Seki, S.2    Dobashi, H.3
  • 61
    • 0034141830 scopus 로고    scopus 로고
    • Cutting edge: Cytolytic effector function in human circulating CD8+ T cells closely correlates with CD56 surface expression
    • Pittet MJ, Speiser DE, Valmori D, Cerottini JC, Romero P. Cutting edge: cytolytic effector function in human circulating CD8+ T cells closely correlates with CD56 surface expression. J Immunol 2000 164 : 1148 52.
    • (2000) J Immunol , vol.164 , pp. 1148-52
    • Pittet, M.J.1    Speiser, D.E.2    Valmori, D.3    Cerottini, J.C.4    Romero, P.5
  • 62
    • 2442484053 scopus 로고    scopus 로고
    • Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses
    • Sakaguchi S. Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004 22 : 531 62.
    • (2004) Annu Rev Immunol , vol.22 , pp. 531-62
    • Sakaguchi, S.1
  • 63
    • 0037364976 scopus 로고    scopus 로고
    • Regulatory T cells in transplantation tolerance
    • Wood KJ, Sakaguchi S. Regulatory T cells in transplantation tolerance. Nat Rev Immunol 2003 3 : 199 210.
    • (2003) Nat Rev Immunol , vol.3 , pp. 199-210
    • Wood, K.J.1    Sakaguchi, S.2
  • 64
    • 33747889822 scopus 로고    scopus 로고
    • Calcineurin inhibitors, but not rapamycin, reduce percentages of CD4+CD25+FOXP3+ regulatory T cells in renal transplant recipients
    • Segundo DS, Ruiz JC, Izquierdo M, et al. Calcineurin inhibitors, but not rapamycin, reduce percentages of CD4+CD25+FOXP3+ regulatory T cells in renal transplant recipients. Transplantation 2006 82 : 550 7.
    • (2006) Transplantation , vol.82 , pp. 550-7
    • Segundo, D.S.1    Ruiz, J.C.2    Izquierdo, M.3
  • 65
    • 33745633856 scopus 로고    scopus 로고
    • Inhibition of CD4+CD25+ T-cell function by calcineurin-dependent interleukin-2 production
    • Zeiser R, Nguyen VH, Beilhack A, et al. Inhibition of CD4+CD25+ T-cell function by calcineurin-dependent interleukin-2 production. Blood 2006 108 : 390 9.
    • (2006) Blood , vol.108 , pp. 390-9
    • Zeiser, R.1    Nguyen, V.H.2    Beilhack, A.3
  • 66
    • 20944446276 scopus 로고    scopus 로고
    • Effects of immunosuppressants on induction of regulatory cells after intratracheal delivery of alloantigen
    • Shibutani S, Inoue F, Aramaki O, et al. Effects of immunosuppressants on induction of regulatory cells after intratracheal delivery of alloantigen. Transplantation 2005 79 : 904 13.
    • (2005) Transplantation , vol.79 , pp. 904-13
    • Shibutani, S.1    Inoue, F.2    Aramaki, O.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.